Condition (MeSH)
Lymphoma, AIDS-Related
ClinicalTrials.gov lists 25 trials for Lymphoma, AIDS-Related or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 5.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
25 of the 25 trials are tagged with Lymphoma, AIDS-Related itself; the rest are tagged with a narrower condition beneath it.
When did Lymphoma, AIDS-Related trials start? (15)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Not applicable
- Observational
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2023 | 1 |
| 2022 | 1 |
| 2021 | 1 |
| 2018 | 1 |
| 2017 | 1 |
| 2016 | 1 |
| 2015 | 2 |
| 2008 | 3 |
| 2007 | 2 |
Showing 10 of 15 earlier years.
No forecast is made for this condition: it averages 0.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Lymphoma, AIDS-Related trials in? (6)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 2 |
| Phase 1/2 | 2 |
| Phase 2 | 10 |
| Not applicable | 3 |
| Observational | 7 |
| Expanded access | 1 |
How many Lymphoma, AIDS-Related trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 2 |
| Active, not recruiting | 2 |
| Completed | 13 |
| Terminated | 2 |
| Withdrawn | 3 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Lymphoma, AIDS-Related trials? (9)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Cancer Institute (NCI) | 5 |
| AIDS Malignancy Consortium | 3 |
| Atara Biotherapeutics | 1 |
| Fondation Ophtalmologique Adolphe de Rothschild | 1 |
| French National Agency for Research on AIDS and Viral Hepatitis | 1 |
Showing 5 of 9 sponsors.
Which drugs are being tested for Lymphoma, AIDS-Related? (5)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| RITUXIMAB | 6 |
| Cytoxan | 4 |
| Prednisone | 3 |
| Procarbazine | 2 |
| EPOETIN ALFA | 2 |
Interventions as named in the registry (10)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Etoposid | 6 |
| Filgrastime (G-CSF) | 4 |
| Doxorubicine | 3 |
| Vincristina | 3 |
| Cytarabine IT | 2 |
Showing 5 of 10 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Lymphoma, AIDS-Related trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Febrile neutropenia | 15 | 3 |
| Headache | 6 | 2 |
| Anemia | 5 | 2 |
| Febrile Neutropenia | 5 | 1 |
| Dehydration | 4 | 3 |
Showing 5 of 10 adverse events.
Which publications cover Lymphoma, AIDS-Related? (68)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Cause-specific mortality after diagnosis of cancer among HIV-positive patients: A collaborative analysis of cohort studies. | International journal of cancer | 2020 | Yes |
| Impact of Myc in HIV-associated non-Hodgkin lymphomas treated with EPOCH and outcomes with vorinostat (AMC-075 trial). | Blood | 2020 | Yes |
| Brentuximab vedotin with AVD shows safety, in the absence of strong CYP3A4 inhibitors, in newly diagnosed HIV-associated Hodgkin lymphoma. | AIDS (London, England) | 2018 | Yes |
| High frequency of identical clonal immunoglobulin DNA in pre-treatment tumor and plasma from untreated patients with HIV-associated lymphoma: prospective multicenter trial of the AIDS malignancies consortium (AMC 064). | Leukemia & lymphoma | 2017 | Yes |
| Autologous hematopoietic cell transplantation for HIV-related lymphoma: results of the BMT CTN 0803/AMC 071 trial. | Blood | 2016 | Yes |
Showing 5 of 68 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.